Intrinsic Value of S&P & Nasdaq Contact Us

Smith & Nephew plc SNN NYSE

NYSE • Healthcare • Medical - Devices • GB • USD

SharesGrow Score
69/100
4/7 Pass
SharesGrow Intrinsic Value
$60.44
+76%
Analyst Price Target
$37.50
+9.2%

Smith & Nephew plc (SNN) generated $1.29B in operating cash flow for fiscal year 2025. After capital expenditures of $434.01M, free cash flow was $853.99M.

Free cash flow margin was 13.8% of revenue. Cash conversion ratio was 2.06x, indicating earnings are backed by cash.

The company returned $330.77M in dividends and $503.17M in share buybacks to shareholders during the period.

Criteria supported by this page:

  • HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
  • MOAT (71/100, Pass) — $853.99M (13.8% FCF margin) supports a durable competitive advantage
  • INCOME (55/100) — Cash conversion ratio was 2.06x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 69/100 with 4/7 criteria passed.

SharesGrow 7-Criteria Score
69/100
SG Score
View full scorecard →
VALUE
69/100
Price-to-Earnings & upside
→ Valuation
~
FUTURE
40/100
Analyst consensus
→ Forecast
PAST
100/100
→ Income
~
HEALTH
67/100
Debt-to-Equity & liquidity
Proven by this page
MOAT
71/100
Proven by this page
GROWTH
83/100
→ Income
~
INCOME
55/100
→ Income
Smith & Nephew plc Cash Flow History
Metric TTM FY2025 FY2024 FY2023 FY2022
Operating Cash Flow $2.28B$1.29B$987M$608M$468M
Capital Expenditure $-815.01M$-434.01M$-381M$-427M$-358M
Free Cash Flow $1.46B$853.99M$606M$181M$110M
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message